Precigen
Open
$4.50
Prev. Close
$4.51
High
$4.50
Low
$4.44
Market Snapshot
$1.57B
-4.1
-0.48
$3.93M
160
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 160 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 160 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Recently from Cashu
Precigen Partners with RRPF to Raise Awareness for Recurrent Respiratory Papillomatosis (RRP)
On June 11, 2026, Precigen, Inc. (Ticker: PGEN) joins forces with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to acknowledge the third annual International RRP Awareness Day. This obser…
Precigen Achieves FDA Approval for PAPZIMEOS™ in Treating Recurrent Respiratory Papillomatosis
Precigen (Ticker: PGEN) secures a vital milestone in the treatment of recurrent respiratory papillomatosis (RRP) with FDA approval for its therapy PAPZIMEOS™. This development marks a significant adva…
Precigen Expects Over $18 Million in First-Quarter Sales for PAPZIMEOS Following J-Code Approval
In early April 2026, Precigen Inc. announces its expectations for first-quarter sales of its respiratory therapy, PAPZIMEOS, projected to exceed US$18 million. This optimistic forecast comes on the he…
Precigen Develops PAPZIMEOS™ for Treating Respiratory Papillomatosis and Advances in Immunology
Precigen Advances in Immunology: New Strategies for Treating Respiratory Papillomatosis In a notable development for the biopharmaceutical landscape, Precigen, Inc. reveals its focus on addressing sub…